HEMISPHERX BIOPHARMA INC Business Operations Contracts & Agreements
18 Contracts & Agreements
- Sales Agreements (3 contracts)
- Services Agreements (9)
- Supply Agreements (3)
- Termination Agreements (3)
- Independent Contractor Services Agreement with Casper H. J. van Eijck (Filed With SEC on April 7, 2023)
- December 5, 2022 Master Service Agreement between Sterling Pharma Solutions Limited and AIM ImmunoTech Inc (Filed With SEC on March 31, 2023)
- August 10, 2022 Termination agreement with Shenzhen Smoore Technology Limited (Filed With SEC on August 15, 2022)
- March 8, 2022 Change order to Master Service Agreement with Pharmaceutics International Inc. as a Fill & Finish provider for Ampligen (Filed With SEC on March 31, 2022)
- March 1, 2022 Amendment to Clinical Trial Agreement with hVIVO Services Ltd dated September 27, 2021 (Filed With SEC on March 31, 2022)
- September 27, 2021 Clinical Trial Agreement with hVIVO Services Limited (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (Filed With SEC on November 15, 2021)
- July 8, 2021 Reservation and Start-Up Agreement with hVIVO Services Limited (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (Filed With SEC on August 16, 2021)
- May 12, 2021 Amendment to the Renewed Sales, Marketing, Distribution and Supply Agreement with GPPharm. (Portions of this Agreement have been redacted in compliance with... (Filed With SEC on May 17, 2021)
- December 23, 2020 Amendment to Master Service Agreement with Pharmaceutics International Inc. as a Fill & Finish provider for Ampligen (Filed With SEC on March 31, 2021)
- December 22, 2020 Master Service Agreement with Pharmaceutics International Inc. as a Fill & Finish provider for Ampligen (Filed With SEC on March 31, 2021)
- June 23, 2020, Specialized Services Agreement with Utah State University. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (Filed With SEC on August 14, 2020)
- Notice of Termination of Equity Distribution Agreement, dated as of July 23, 2012, by and between Hemispherx Biopharma, Inc. and Maxim Group LLC (Filed With SEC on July 22, 2019)
- Chardan Equity Distribution Agreement Termination letter (Filed With SEC on December 11, 2018)
- Sales,Marketing, Distribution, and Supply Agreement {***} (Filed With SEC on May 16, 2016)
- Sales, Marketing, Distribution, and Supply Agreement (Filed With SEC on August 12, 2015)
- Sales, Marketing, Distribution, and Supply Agreement (Filed With SEC on March 19, 2015)
- FourthAmendment to Supply Agreement (Filed With SEC on March 14, 2012)
- Amendmentto Supply Agreement with Hollister-Stier Laboratories LLC (Filed With SEC on March 12, 2010)
